All sponsors

Pfizer $PFE

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS126
PHASE 3 / 2-393
RECRUITING78
READOUTS ≤12 MONTHS35
READOUT SLIPPED >6 MO53%

Delay Index: of 81 active trials registered more than a year ago, 43 have moved their primary completion (readout) date by more than 6 months since first registration (median +6.2 months). See all sponsors →

Open Pfizer on the live radar map → 📅 $PFE readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Lorlatinib
NCT03052608
P3Active, not recruitingCarcinoma, Non-Small-Cell Lung2962020-03-20 (+4 mo)
TALAPRO-2
NCT03395197
P3Active, not recruitingmCRPC10542022-10-03 (+6 mo)
BENEGENE-2
NCT03861273
P3Active, not recruitingHemophilia B512022-11-16 (+10 mo)
Enzalutamide
NCT02319837
P3Active, not recruitingHormone Sensitive Prostate Cancer; Prostate Cancer10682023-01-31 (+26 mo)
Tucatinib
NCT04721977
P2Active, not recruitingBreast Cancer662023-07-17 (+6 mo)
PF-06939926
NCT04281485
P3Active, not recruitingDuchenne Muscular Dystrophy1142024-05-15 (+25 mo)
AFFINE
NCT04370054
P3Active, not recruitingHemophilia A772024-06-17 (+22 mo)
CREST
NCT04165317
P3Active, not recruitingNon-muscle Invasive Bladder Cancer10682024-12-02 (+6 mo)
VERITAC-2
NCT05654623
P3Active, not recruitingAdvanced Breast Cancer6242025-01-31 (+6 mo)
Encorafenib
NCT04607421
P3Active, not recruitingNeoplasms8412025-03-01 (+5 mo)
vepdegestrant
NCT06206837
P1/2Active, not recruitingBreast Cancer712025-09-05 (-8 mo)
PF-07220060 CDK4 inhibitor
NCT06105632
P2Active, not recruitingAdvanced or Metastatic Breast Cancer3332026-01-12 (+2 mo)
talazoparib plus enzalutamide
NCT04821622
P3Active, not recruitingProstate Cancer5992026-02-18 (+14 mo)
MAGNETISMM-5
NCT05020236
P3RecruitingMultiple Myeloma8932026-02-26 (+10 mo)
SEAMARK
NCT05217446
P2Active, not recruitingMetastatic Colorectal Cancer1082026-06-19 (+4 mo)
nirmatrelvir
NCT05261139
P3RecruitingCOVID-191602026-07-30 (+41 mo)
Elranatamab
NCT06152575
P3RecruitingMultiple Myeloma4922026-08-26 (+9 mo)
Encorafenib
NCT04657991
P3Active, not recruitingMelanoma2572026-10-30 (+38 mo)
PF-07275315
NCT05995964
P2Active, not recruitingAtopic Dermatitis5072026-11-12 (+7 mo)
Rimegepant
NCT06641466
P3RecruitingMenstrual Migraine7232026-11-29 (+6 mo)
B7981027
NCT07029711
P3Active, not recruitingSevere Alopecia Areata2082026-12-02 (-5 mo)
VLA15
NCT07500506
P3RecruitingLyme Disease17122026-12-04
Ritlecitinib
NCT07228390
P2Active, not recruitingHidradenitis Suppurativa1282026-12-08 (-3 mo)
Ritlecitinib 50 mg
NCT07219615
P2RecruitingChronic Spontaneous Urticaria2002026-12-25
VERITAC-3
NCT05909397
P3Active, not recruitingBreast Cancer592026-12-30 (-20 mo)
Avelumab
NCT05059522
P3Active, not recruitingAdvanced Malignancies; NSCLC772026-12-31 (+12 mo)
PF-07104091 monotherapy dose escalation
NCT04553133
P2Active, not recruitingSmall Cell Lung Cancer; Ovarian Cancer1572026-12-31 (+20 mo)
RENOIR
NCT05035212
P3Active, not recruitingLower Respiratory Tract Illness388612027-01-18 (+31 mo)
RSVpreF
NCT07653100
P3RecruitingRespiratory Syncytial Virus (RSV)5402027-01-25
PF-07220060 + PF-07104091 combination dose escalation
NCT05262400
P1/2Active, not recruitingBreast Cancer; Solid Tumors2352027-02-26 (+4 mo)
MEVPRO-1
NCT06551324
P3Active, not recruitingMetastatic Castrate Resistant Prostate Cancer (mCRPC)6092027-02-28 (+14 mo)
PG4
NCT06524414
P2Active, not recruitingPneumococcal Disease6052027-03-04 (+8 mo)
PF-07275315
NCT06977581
P2RecruitingAsthma2522027-03-08
tofacitinib
NCT04624230
P3Active, not recruitingUlcerative Colitis1182027-03-17 (+15 mo)
ARV-471
NCT05548127
P1/2Active, not recruitingBreast Cancer372027-03-24 (+18 mo)
ATM-AVI
NCT05639647
P2RecruitingGram-negative Bacterial Infections482027-03-31 (+15 mo)
Tranquillo LTE
NCT06163326
P3Active, not recruitingVitiligo3942027-03-31 (+8 mo)
CHERISH
NCT06462235
P2RecruitingGram-negative Bacterial Infection482027-04-25 (-5 mo)
PG4 Multivalent Vaccine
NCT07794748
P3Active, not recruitingPneumococcal Disease47012027-04-26
Abrocitinib
NCT06807268
P3Active, not recruitingEczema1512027-05-02 (+1 mo)
RSVpreF
NCT07819097
P3RecruitingAdult; Healthy Participants6002027-05-16
Vaccine Candidate #1
NCT07431853
P2RecruitingHealthy Adults7702027-06-22
PF-07248144
NCT07062965
P3RecruitingBreast Cancer4002027-07-22 (-3 mo)
Tranquillo 2
NCT06072183
P3Active, not recruitingStable Nonsegmental Vitiligo; Active Nonsegmental Vitiligo15712027-07-30
MagnetisMM-7
NCT05317416
P3Active, not recruitingMultiple Myeloma8542027-08-04 (+1 mo)
SOLIS-1
NCT07575932
P2Active, not recruitingOverweight; Obesity9402027-08-04
VESPER-4
NCT07311850
P3Active, not recruitingObesity and Overweight35782027-09-21
ibuzatrelvir
NCT07013474
P3RecruitingCOVID-19 Infection3002027-09-28 (+10 mo)
PF-06821497
NCT06629779
P3RecruitingMetastatic Castration-Resistant Prostate Cancer9002027-09-30 (+14 mo)
ibuzatrelvir
NCT06679140
P3RecruitingCOVID-19 SARS-CoV-2 Infection23302027-10-01 (+10 mo)
PF-08653944
NCT07400653
P3Active, not recruitingObesity; Overweight and/or Obesity10782027-10-12
PF-08634404
NCT07227012
P1/2RecruitingCarcinoma, Hepatocellular; Hepatocellular Cancer1382027-10-18
Disitamab vedotin
NCT06966453
P1/2Active, not recruitingBreast Cancer; Breast Neoplasms742027-10-25 (+6 mo)
PF-08634404
NCT07227415
P1/2RecruitingCarcinoma, Renal Cell; Advanced Renal Cell Carcinoma2242027-11-02
PG4
NCT07660198
P3RecruitingPneumococcal Disease12002027-12-02
PF-08634404
NCT07421700
P1/2RecruitingUrothelial Cancer; Advanced/Metastatic Urothelial Cancer1322027-12-28
ponsegromab
NCT06989437
P2/3RecruitingCachexia; Metastatic Pancreatic Ductal Adenocarcinoma9822028-01-23 (-11 mo)
VLA15
NCT07226882
P3Active, not recruitingLyme Borreliosis2072028-01-27
PF-08049820
NCT07216027
P2RecruitingAtopic Dermatitis; Eczema, Atopic1652028-02-02 (+5 mo)
RSVpreF Vaccine
NCT07768345
P3RecruitingRespiratory Syncytial Virus (RSV)4402028-02-02
Semaglutide
NCT07845500
P3RecruitingObesity; Overweight and/or Obesity6602028-02-16
RSVpreF
NCT06866405
P3RecruitingRSV Infection5502028-02-24
Tilrekimig
NCT07765888
P3RecruitingAtopic Dermatitis3752028-03-10
PF-08046054
NCT07144280
P3RecruitingNon-small Cell Carcinoma; Non-Small Cell Lung Cancer Metastatic6802028-03-10
Berobenatide
NCT07792954
P3RecruitingObesity; Overweight3002028-03-14
ALLEGRO-100
NCT06873945
P3RecruitingAlopecia Areata6742028-03-19 (+12 mo)
PF-08634404
NCT07476287
P2RecruitingSmall Cell Lung Cancer; Small Cell Lung Cancer ( SCLC )402028-03-24
Ritlecitinib 100 mg
NCT07733765
P3RecruitingAlopecia Areata3362028-04-26
Berobenatide
NCT07823608
P3RecruitingApnea; Sleep Disorders2582028-04-30
PF-08653944
NCT07595549
P3RecruitingObesity; Overweight and/or Obesity9542028-05-04
Low Dose PF-07328948
NCT06991257
P2RecruitingHeart Failure6202028-05-08 (+6 mo)
VESPER-OSA 2
NCT07881757
P3RecruitingApnea; Sleep Disorders2582028-06-01
Berobenatide
NCT07874633
P3RecruitingObesity; Overweight4322028-06-06
PF-08634404
NCT07489066
P2RecruitingCarcinoma; Non-Small-Cell Lung1202028-07-29
Berobenatide
NCT07915609
P3RecruitingObesity; Overweight and/or Obesity7562028-08-21
Berobenatide
NCT07919678
P3RecruitingObesity; Overweight6562028-08-22
Sigvotatug Vedotin
NCT06758401
P3RecruitingNon-Small Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung7142028-09-05
Tilrek
NCT07783425
P3RecruitingAtopic Dermatitis13752028-09-08
BASIS KIDS
NCT05611801
P3RecruitingHemophilia A; Hemophilia B1002028-09-10
Mevrometostat
NCT07028853
P3RecruitingMetastatic Castration Sensitive Prostate Cancer (mCSPC); Hormone Sensitive Prostate Cancer10002028-09-12
Berobenatide
NCT07932925
P3Not yet recruitingUrinary Incontinence, Stress; Overweight and/or Obesity9002028-10-13
Rimegepant
NCT07729462
P3RecruitingPreventive Treatment of Migraine4002028-10-21
Multivalent Group B streptococcus vaccine
NCT07160244
P3RecruitingHealthy60002028-11-06
20vPnC
NCT07754539
P3RecruitingPneumococcal Diseases12502028-11-30
BEETHOVEN
NCT07282665
P3RecruitingClostridoides Difficile Associated Disease325002028-12-11
PG4
NCT07573462
P3RecruitingPneumococcal Disease24002028-12-30
FourLight-3
NCT06760637
P3Active, not recruitingBreast Cancer10352029-01-02
Rimegepant/BHV3000
NCT04649242
P3RecruitingPediatric Migraine21002029-01-09 (+72 mo)
RSVpreF (Regimen A)
NCT07885956
P3Not yet recruitingRespiratory Syncytial Virus (RSV)7502029-02-07
Berobenatide
NCT07794774
P3RecruitingObesity1972029-02-21
PF-08634404
NCT07222566
P3RecruitingAdvanced Non-Small Cell Lung Cancer; Non-Small Cell Lung Cancer14102029-02-27
PF-08634404
NCT07227298
P1/2RecruitingAdvanced/Metastatic Non-Small Cell Lung Cancer; Carcinoma, Non-Small Cell Lung1622029-03-08
Berobenatide
NCT07794761
P3RecruitingObesity1802029-03-14
Rimegepant
NCT05156398
P3RecruitingMigraine6402029-03-27 (+31 mo)
Abrocitinib
NCT07823595
P3Not yet recruitingAtopic Dermatitis902029-04-10
PF-08634404
NCT07578649
P3RecruitingEndometrial Neoplasms; Endometrial Cancer6002029-06-01
tilrekimig
NCT07772921
P3RecruitingAsthma11002029-06-01
PG4
NCT07629440
P3RecruitingPneumococcal Disease32302029-06-05
tilrekimig
NCT07869043
P3RecruitingAsthma11002029-06-07
Etrasimod
NCT05287126
P2RecruitingUlcerative Colitis362029-06-16 (+56 mo)
ELEVATE UC OLE
NCT03950232
P3Active, not recruitingUlcerative Colitis8962029-06-19 (+57 mo)
marstacimab
NCT07923981
P3RecruitingHemophilia A or B952029-07-02
KAT6
NCT04606446
P2RecruitingLocally Advanced or Metastatic ER+ HER2- Breast Cancer; Locally Advanced or Metastatic Castration-resistant Prostate Cancer3202029-08-27 (+60 mo)
CDK4i
NCT04557449
P2RecruitingLiposarcoma; Prostate Cancer4302029-10-07 (+61 mo)
Palbociclib
NCT05226871
P2Active, not recruitingBreast Cancer; Head and Neck Cancer352029-12-31 (+44 mo)
PF-08634404
NCT07222800
P3RecruitingIntestinal Neoplasms; Gastrointestinal Neoplasms8002030-02-23 (-1 mo)
Rimegepant
NCT06616194
P3Active, not recruitingMigraine6362030-02-26 (+27 mo)
PF-08634404
NCT07226999
P2/3RecruitingSmall Cell Lung Cancer (SCLC)5502030-06-14
B7981028
NCT07029828
P3RecruitingSevere Alopecia Areata1402030-06-26
PF-06823859
NCT05895786
P3RecruitingMyositis3182030-07-29 (+56 mo)
Rimegepant (PF-07899801)
NCT04743141
P3RecruitingAcute Treatment of Migraine6002030-07-31 (+82 mo)
PF-06741086
NCT05145127
P3RecruitingHemophilia A; Hemophilia B2452030-07-31
ELEVATE-UCkids
NCT07470879
P2RecruitingColitis, Ulcerative242030-09-08
MagnetisMM-6
NCT05623020
P3RecruitingMultiple Myeloma10602030-10-18 (+28 mo)
COPD
NCT07363694
P2/3RecruitingModerate to Severe Chronic Obstructive Pulmonary Disease11562030-10-24
Osivelotor
NCT05431088
P2/3RecruitingSickle Cell Disease3892030-12-30 (+51 mo)
PF-08154225
NCT07782450
P1/2Not yet recruitingSystemic Lupus Erythematosus; Rheumatoid Arthritis542031-02-22
RSVpreF
NCT07839871
P3RecruitingRespiratory Syncytial Virus (RSV)9202031-03-30
C. difficile vaccine (previously studied formulation).
NCT05805826
P1/2Active, not recruitingClostridoides Difficile Associated Disease9362031-06-19 (+21 mo)
PF-08634404
NCT07392892
P2/3RecruitingUntreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma; Metastatic Gastric Cancer8402031-07-22
Dazukibart
NCT06698796
P3RecruitingDermatomyositis; Polymyositis2112031-07-29 (+45 mo)
Abrocitinib
NCT06807281
P3RecruitingAtopic Dermatitis4502032-02-22 (+1 mo)
Atirmociclib
NCT07890597
P3Not yet recruitingEarly Breast Cancer; Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-)38002032-04-13
Inotuzumab ozogamicin
NCT05748171
P2RecruitingACUTE LYMPHOBLASTIC LEUKEMIA1002033-05-21 (+67 mo)
Tilrekimig
NCT07839884
P3Not yet recruitingModerate to Severe Chronic Obstructive Pulmonary Disease13602034-05-12
Testing of hepatic AAV Vector integration
NCT05568719
P3RecruitingHemophilia A; Hemophilia B1732040-02-25 (+66 mo)